Xi'an Medical University, No 74 Hanguangbei Road, Xi'an, 710068, Shaanxi, China.
Department of Neurology, Shaanxi Provincial People's Hospital, No 256 Youyixi Road, Xi'an, 710068, Shaanxi, China.
J Mol Neurosci. 2019 Nov;69(3):444-449. doi: 10.1007/s12031-019-01373-1. Epub 2019 Jul 17.
Ischemic stroke is a disease that affects peoples health and quality of life. Cystatin C has been found as a new biomarker of cardiovascular disease. We performed this meta-analysis to assess the relationship between cystatin C and the risk of ischemic stroke. The studies on looking at the association between cystatin C and ischemic stroke were identified from inception to November 18, 2018. We performed a random-effects meta-analysis using mean difference. Nine studies with a total of 3773 ischemic stroke patients were included into the meta-analysis. Our results showed that patients with ischemic stroke had significantly higher serum cystatin C concentrations compared with the participants without ischemic stroke (pooled mean difference, 0.11; 95% confidence interval (CI), 0.00-0.22; P = 0.04), in particular acute ischemic stroke and subclinical cerebral infarction (mean difference, 0.23; 95% CI, 0.11-0.36; P = 0.0003 and mean difference, 0.07; 95% CI, 0.05-0.09; P < 0.00001, respectively). Cystatin C was associated with ischemic stroke, and it could be considered a predictor for the risk of ischemic stroke, especially in acute ischemic stroke and subclinical cerebral infarction.
缺血性脑卒中是一种影响人们健康和生活质量的疾病。半胱氨酸蛋白酶抑制剂 C 已被发现是心血管疾病的一种新的生物标志物。我们进行了这项荟萃分析，以评估半胱氨酸蛋白酶抑制剂 C 与缺血性脑卒中风险之间的关系。从研究开始到 2018 年 11 月 18 日，我们检索了评估半胱氨酸蛋白酶抑制剂 C 与缺血性脑卒中之间关联的研究。我们使用均数差值进行了随机效应荟萃分析。共有 9 项研究，总计 3773 例缺血性脑卒中患者纳入荟萃分析。我们的结果表明，与无缺血性脑卒中的参与者相比，缺血性脑卒中患者的血清半胱氨酸蛋白酶抑制剂 C 浓度显著升高（合并均数差值，0.11；95%置信区间[CI]，0.00-0.22；P = 0.04），尤其是急性缺血性脑卒中患者和亚临床脑梗死患者（均数差值，0.23；95%CI，0.11-0.36；P = 0.0003 和均数差值，0.07；95%CI，0.05-0.09；P < 0.00001）。半胱氨酸蛋白酶抑制剂 C 与缺血性脑卒中相关，可被视为缺血性脑卒中风险的预测因子，尤其是在急性缺血性脑卒中患者和亚临床脑梗死患者中。
